ADMA — ADMA Biologics Cashflow Statement
0.000.00%
Last trade - 00:00- $3.43bn
- $3.41bn
- $426.45m
- 58
- 35
- 35
- 37
Annual cashflow statement for ADMA Biologics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -75.7 | -71.6 | -65.9 | -28.2 | 198 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 3.58 | 5.46 | 17.6 | 38.8 | 15.8 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -33.8 | -51.7 | -18.3 | -10.1 | -18.5 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -102 | -112 | -59.5 | 8.8 | 119 |
| Capital Expenditures | -12.7 | -13.5 | -13.9 | -4.98 | -8.57 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.002 | 0 | — | — | — |
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -12.7 | -13.5 | -13.9 | -4.98 | -8.57 |
| Financing Cash Flow Items | -0.83 | -0.062 | -7.68 | -16.5 | -5.8 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 144 | 121 | 109 | -39 | -58.3 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 29.2 | -4.83 | 35.4 | -35.2 | 51.8 |